ArticleJournal of cardiac failure2020
Optimizing The Management of Obese HFpEF Phenotype: Can We Mind Both The Heart and The Kidney?
Article in Journal of cardiac failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Abdominal obesity is associated with increased worsening renal function risk in patients with heart failure with preserved ejection fraction.BMC cardiovascular disorders · 2024Trial
- Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review.Current heart failure reports · 2025Review
- High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice.Current cardiology reviews · 2022Review
- Cellular and molecular pathobiology of heart failure with preserved ejection fraction.Nature reviews. Cardiology · 2021Review
- Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity.Frontiers in physiology · 2021Review
- Range of adiposity and cardiorenal syndrome.World journal of diabetes · 2020Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adverse prognostic implications of significant renal dysfunction during treatment of acute decompensated heart failure (HF) in patients with obese HF and preserved ejection fraction (HFpEF) provide strong rationale for development of therapeutic strategies that enhance decongestion while preserving renal function in this cohort. The combination of preload sensitivity, intrinsic renal dysfunction related to obesity, glomerular hyperfiltration, reversible renal hypoperfusion (poor renal arterial perfusion and renal venous congestion), and decreased systemic vascular resistance in obesity may predispose patients to renal hemodynamic compromise during diuresis. Thus, serum creatinine increase should not be evaluated in isolation but rather considered in the context of the entire clinical picture in patients with obese HFpEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.